Krystal Biotech (KRYS) CAO sells shares and receives fresh stock awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Krystal Biotech, Inc. Chief Accounting Officer Kathryn Romano reported a mix of stock sales, vesting, and new equity awards. On March 2, 2026, she completed an open-market sale of 750 shares of common stock at $267.60 per share under a pre-arranged Rule 10b5-1 trading plan, leaving 22,366 common shares held directly.
On February 27, 2026, 7,500 performance stock units vested after meeting 2024 performance goals, and 550 restricted stock units vested from a 2025 grant, both converting into common shares. To cover tax withholding on these vestings, 3,262 and 240 common shares, respectively, were surrendered to the company at a reference price of $275.64 per share.
Also on February 27, Romano received new equity incentives: a stock option for 13,575 shares and a new grant of 5,442 restricted stock units, each vesting in four equal annual installments beginning February 27, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 750 shares ($200,700)
Net Sell
9 txns
Insider
ROMANO KATHRYN
Role
Chief Accounting Officer
Sold
750 shs ($201K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 750 | $267.60 | $201K |
| Exercise | Performance Stock Units | 7,500 | $0.00 | -- |
| Exercise | Restricted Stock Units | 550 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 13,575 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 5,442 | $0.00 | -- |
| Exercise | Common Stock | 7,500 | $0.00 | -- |
| Tax Withholding | Common Stock | 3,262 | $275.64 | $899K |
| Exercise | Common Stock | 550 | $0.00 | -- |
| Tax Withholding | Common Stock | 240 | $275.64 | $66K |
Holdings After Transaction:
Common Stock — 22,366 shares (Direct);
Performance Stock Units — 0 shares (Direct);
Restricted Stock Units — 1,650 shares (Direct);
Stock Option (Right to Buy) — 13,575 shares (Direct)
Footnotes (1)
- 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026. Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026. The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026. Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026. The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan. The stock options vest in four equal annual installments beginning on February 27, 2027. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates. The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.
FAQ
What insider transactions did Kathryn Romano report at Krystal Biotech (KRYS)?
Kathryn Romano reported an open-market sale of 750 Krystal Biotech shares, vesting of performance and restricted stock units into common shares, tax-withholding share surrenders, and new grants of stock options and restricted stock units as part of her equity compensation package.
What equity awards vested for Kathryn Romano at Krystal Biotech (KRYS)?
7,500 performance stock units and 550 restricted stock units vested for Kathryn Romano. Each unit converted into one share of Krystal Biotech common stock after meeting performance criteria and service conditions tied to specific vesting dates approved by the company.
What new stock option and RSU grants did Kathryn Romano receive from Krystal Biotech (KRYS)?
She received a stock option for 13,575 shares and a grant of 5,442 restricted stock units. Both awards vest in four equal annual installments starting February 27, 2027, contingent on her continued service to Krystal Biotech on each vesting date.